{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:09:50Z","timestamp":1789070990126,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cardiovasc Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Truncating variants in the\n                    <jats:italic>ALPK3<\/jats:italic>\n                    gene (encoding alpha protein kinase 3) cause severe cardiomyopathy for which no curative treatment exists\n                    <jats:sup>1\u20133<\/jats:sup>\n                    . Here we establish an adeno-associated virus (AAV)-mediated gene replacement therapy to deliver full-length human\n                    <jats:italic>ALPK3<\/jats:italic>\n                    . AAV-\n                    <jats:italic>ALPK3<\/jats:italic>\n                    prevented disease in neonatal\n                    <jats:italic>Alpk3-<\/jats:italic>\n                    mutant mice and reversed established pathology in adults, with proteomic analysis demonstrating reversal of more than 95% of the molecular disease signature. Beyond ALPK3 deficiency, we explored broader therapeutic potential based on ALPK3\u2019s regulatory role in proteostasis, a pathway commonly disrupted across cardiomyopathies. ALPK3 expression is reduced in cardiomyocytes with\n                    <jats:italic>TTN<\/jats:italic>\n                    -truncating variants, the most prevalent cause of dilated cardiomyopathy, and the encoded titin protein has a protein quality control network in common with ALPK3. AAV-\n                    <jats:italic>ALPK3<\/jats:italic>\n                    restored contractile function in human cardiac organoids with an\n                    <jats:italic>ALPK3<\/jats:italic>\n                    - or\n                    <jats:italic>TTN<\/jats:italic>\n                    -truncating variant. These findings provide proof of concept for\n                    <jats:italic>ALPK3<\/jats:italic>\n                    gene therapy in patients with\n                    <jats:italic>ALPK3<\/jats:italic>\n                    cardiomyopathy and reveal potential for indication expansion to cardiomyopathies associated with\n                    <jats:italic>TTN<\/jats:italic>\n                    -truncating variants, which are not amenable to gene replacement therapy due to size limitations.\n                  <\/jats:p>","DOI":"10.1038\/s44161-026-00843-1","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T14:03:00Z","timestamp":1787148180000},"page":"795-806","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Alpha protein kinase 3 gene therapy restores heart function in mouse and human models of cardiomyopathy"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3754-6405","authenticated-orcid":false,"given":"James W.","family":"McNamara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen B.","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7959-001X","authenticated-orcid":false,"given":"Rebecca","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-5123-0885","authenticated-orcid":false,"given":"Yinghan","family":"She","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5451-294X","authenticated-orcid":false,"given":"Hannah","family":"Huckstep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5368-8391","authenticated-orcid":false,"given":"Lina H. H.","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1929-2034","authenticated-orcid":false,"given":"Neda R.","family":"Mehdiabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhavan S.","family":"Venkatesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Griffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9735-2595","authenticated-orcid":false,"given":"Richard J.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1658-1447","authenticated-orcid":false,"given":"Christina V.","family":"Theodoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-6136","authenticated-orcid":false,"given":"Drew M.","family":"Titmarsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-9744","authenticated-orcid":false,"given":"Sean J.","family":"Humphrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-7463","authenticated-orcid":false,"given":"Enzo R.","family":"Porrello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1052-7407","authenticated-orcid":false,"given":"David A.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"843_CR1","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jacc.2015.10.093","volume":"67","author":"R Almomani","year":"2016","unstructured":"Almomani, R. et al. Biallelic truncating mutations in ALPK3 cause severe pediatric cardiomyopathy. J. Am Coll. Cardiol. 67, 515\u2013525 (2016).","journal-title":"J. Am Coll. Cardiol."},{"key":"843_CR2","doi-asserted-by":"crossref","unstructured":"Hespe, S. et al. Clinical validity of autosomal dominant ALPK3 loss-of-function variants as a cause of hypertrophic cardiomyopathy. Circ. Genom. Precis. Med. 18, e004976 (2025).","DOI":"10.1161\/CIRCGEN.124.004976"},{"key":"843_CR3","doi-asserted-by":"publisher","first-page":"2586","DOI":"10.1093\/eurheartj\/ehw160","volume":"37","author":"DG Phelan","year":"2016","unstructured":"Phelan, D. G. et al. ALPK3-deficient cardiomyocytes generated from patient-derived induced pluripotent stem cells and mutant human embryonic stem cells display abnormal calcium handling and establish that ALPK3 deficiency underlies familial cardiomyopathy. Eur. Heart J. 37, 2586\u20132590 (2016).","journal-title":"Eur. Heart J."},{"key":"843_CR4","doi-asserted-by":"crossref","unstructured":"Bakalakos, A., Monda, E. & Elliott, P.M. Tailored therapeutics for cardiomyopathies. Nat. Rev. Cardiol. 22, 814\u2013831 (2025).","DOI":"10.1038\/s41569-025-01183-6"},{"key":"843_CR5","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2016.101","volume":"13","author":"EM Antman","year":"2016","unstructured":"Antman, E. M. & Loscalzo, J. Precision medicine in cardiology. Nat. Rev. Cardiol. 13, 591\u2013602 (2016).","journal-title":"Nat. Rev. Cardiol."},{"key":"843_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57481-7","volume":"16","author":"A Greer-Short","year":"2025","unstructured":"Greer-Short, A. et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat. Commun. 16, 2196 (2025).","journal-title":"Nat. Commun."},{"key":"843_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6515","volume":"5","author":"G Mearini","year":"2014","unstructured":"Mearini, G. et al. Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice. Nat. Commun. 5, 5515 (2014).","journal-title":"Nat. Commun."},{"key":"843_CR8","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s44161-023-00370-3","volume":"2","author":"WH Bradford","year":"2023","unstructured":"Bradford, W. H. et al. Plakophilin\u20092 gene therapy prevents and rescues arrhythmogenic right ventricular cardiomyopathy in a mouse model harboring patient genetics. Nat. Cardiovasc. Res. 2, 1246\u20131261 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"843_CR9","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/s44161-023-00378-9","volume":"2","author":"E Kyriakopoulou","year":"2023","unstructured":"Kyriakopoulou, E. et al. Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat. Cardiovasc. Res. 2, 1262\u20131276 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"843_CR10","doi-asserted-by":"crossref","unstructured":"Henry, T. D. et al. Cardiotropic AAV gene therapy for heart failure: a phase 1 trial. Nat. Med. 31, 3845\u20133852 (2025).","DOI":"10.1038\/s41591-025-04011-z"},{"key":"843_CR11","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1038\/s44161-025-00744-9","volume":"4","author":"F Meng","year":"2025","unstructured":"Meng, F. et al. Gene therapy CM-YAPon protects the mouse heart from myocardial infarction. Nat. Cardiovasc. Res. 4, 1616\u20131626 (2025).","journal-title":"Nat. Cardiovasc. Res."},{"key":"843_CR12","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1093\/eurheartj\/ehab424","volume":"42","author":"LR Lopes","year":"2021","unstructured":"Lopes, L. R. et al. Alpha-protein kinase 3 (ALPK3) truncating variants are a cause of autosomal dominant hypertrophic cardiomyopathy. Eur. Heart J. 42, 3063\u20133073 (2021).","journal-title":"Eur. Heart J."},{"key":"843_CR13","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s44161-023-00219-9","volume":"2","author":"JW McNamara","year":"2023","unstructured":"McNamara, J. W. et al. Alpha kinase 3 signaling at the M-band maintains sarcomere integrity and proteostasis in striated muscle. Nat. Cardiovasc. Res. 2, 159\u2013173 (2023).","journal-title":"Nat. Cardiovasc. Res."},{"key":"843_CR14","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1161\/CIRCULATIONAHA.122.059688","volume":"146","author":"R Agarwal","year":"2022","unstructured":"Agarwal, R. et al. Pathogenesis of cardiomyopathy caused by variants in ALPK3, an essential pseudokinase in the cardiomyocyte nucleus and sarcomere. Circulation 146, 1674\u20131693 (2022).","journal-title":"Circulation"},{"key":"843_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.039464","volume":"14","author":"W Feng","year":"2025","unstructured":"Feng, W. et al. \u03b1 Protein kinase 3 is essential for neonatal and adult cardiac function. J. Am. Heart Assoc. 14, e039464 (2025).","journal-title":"J. Am. Heart Assoc."},{"key":"843_CR16","doi-asserted-by":"publisher","first-page":"E8372","DOI":"10.1073\/pnas.1707316114","volume":"114","author":"RJ Mills","year":"2017","unstructured":"Mills, R. J. et al. Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. Proc. Natl Acad. Sci. USA 114, E8372\u2013E8381 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"843_CR17","doi-asserted-by":"publisher","first-page":"112322","DOI":"10.1016\/j.celrep.2023.112322","volume":"42","author":"HK Voges","year":"2023","unstructured":"Voges, H. K. et al. Vascular cells improve functionality of human cardiac organoids. Cell Rep. 42, 112322 (2023).","journal-title":"Cell Rep."},{"key":"843_CR18","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s00424-018-2194-0","volume":"471","author":"LM Dorsch","year":"2019","unstructured":"Dorsch, L. M. et al. Untying the knot: protein quality control in inherited cardiomyopathies. Pflugers Arch. 471, 795\u2013806 (2019).","journal-title":"Pflugers Arch."},{"key":"843_CR19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41586-023-06139-9","volume":"618","author":"CV Theodoris","year":"2023","unstructured":"Theodoris, C. V. et al. Transfer learning enables predictions in network biology. Nature 618, 616\u2013624 (2023).","journal-title":"Nature"},{"key":"843_CR20","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba7721","volume":"370","author":"J Cao","year":"2020","unstructured":"Cao, J. et al. A human cell atlas of fetal gene expression. Science 370, eaba7721 (2020).","journal-title":"Science"},{"key":"843_CR21","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1126\/science.1110463","volume":"308","author":"S Lange","year":"2005","unstructured":"Lange, S. et al. The kinase domain of titin controls muscle gene expression and protein turnover. Science 308, 1599\u20131603 (2005).","journal-title":"Science"},{"key":"843_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.stemcr.2022.11.008","volume":"18","author":"G Huang","year":"2023","unstructured":"Huang, G. et al. Titin-truncating variants in hiPSC cardiomyocytes induce pathogenic proteinopathy and sarcomere defects with preserved core contractile machinery. Stem Cell Rep. 18, 220\u2013236 (2023).","journal-title":"Stem Cell Rep."},{"key":"843_CR23","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","volume":"26","author":"S Bunting","year":"2018","unstructured":"Bunting, S. et al. Gene therapy with BMN 270 results in therapeutic levels of FVIII in mice and primates and normalization of bleeding in hemophilic mice. Mol. Ther. 26, 496\u2013509 (2018).","journal-title":"Mol. Ther."},{"key":"843_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nm1439","volume":"12","author":"P Gregorevic","year":"2006","unstructured":"Gregorevic, P. et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat. Med. 12, 787\u2013789 (2006).","journal-title":"Nat. Med."},{"key":"843_CR25","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1161\/CIRCULATIONAHA.125.074632","volume":"152","author":"W Feng","year":"2025","unstructured":"Feng, W. et al. A novel miniALPK3 gene therapy for ALPK3-associated cardiomyopathy. Circulation 152, 1453\u20131455 (2025).","journal-title":"Circulation"},{"key":"843_CR26","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJMoa1000228","volume":"363","author":"JR Mendell","year":"2010","unstructured":"Mendell, J. R. et al. Dystrophin immunity in Duchenne\u2019s muscular dystrophy. N. Engl. J. Med. 363, 1429\u20131437 (2010).","journal-title":"N. Engl. J. Med."},{"key":"843_CR27","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1093\/cvr\/cvaf200","volume":"121","author":"MY Desai","year":"2025","unstructured":"Desai, M. Y. et al. First-in-human study of TN-201, an AAV9 gene replacement therapy in MYBPC3-associated hypertrophic cardiomyopathy: initial safety, pharmacodynamic, and imaging results from MyPEAK-1. Cardiovasc. Res. 121, 2628\u20132631 (2025).","journal-title":"Cardiovasc. Res."},{"key":"843_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1038\/nmeth.1740","volume":"8","author":"DA Elliott","year":"2011","unstructured":"Elliott, D. A. et al. NKX2-5eGFP\/w hESCs for isolation of human cardiac progenitors and cardiomyocytes. Nat. Meth. 8, 1037\u20131040 (2011).","journal-title":"Nat. Meth."},{"key":"843_CR29","doi-asserted-by":"crossref","unstructured":"Pocock, M. W. et al. Maturation of human cardiac organoids enables complex disease modeling and drug discovery. Nat. Cardiovasc. Res. 4, 821\u2013840 (2025).","DOI":"10.1038\/s44161-025-00669-3"},{"key":"843_CR30","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1038\/s41596-018-0014-9","volume":"13","author":"SJ Humphrey","year":"2018","unstructured":"Humphrey, S. J., Karayel, O., James, D. E. & Mann, M. High-throughput and high-sensitivity phosphoproteomics with the EasyPhos platform. Nat. Protoc. 13, 1897\u20131916 (2018).","journal-title":"Nat. Protoc."},{"key":"843_CR31","first-page":"100059","volume":"7","author":"M Meyer-Jens","year":"2024","unstructured":"Meyer-Jens, M. et al. Sacubitril\/valsartan reduces proteasome activation and cardiomyocyte area in an experimental mouse model of hypertrophy. J. Mol. Cell Cardiol. Plus 7, 100059 (2024).","journal-title":"J. Mol. Cell Cardiol. Plus"},{"key":"843_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1126\/science.aax6234","volume":"367","author":"SR Srivatsan","year":"2020","unstructured":"Srivatsan, S. R. et al. Massively multiplex chemical transcriptomics at single-cell resolution. Science 367, 45\u201351 (2020).","journal-title":"Science"},{"key":"843_CR33","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e4 (2019).","journal-title":"Cell Syst."}],"container-title":["Nature Cardiovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00843-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00843-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:43:20Z","timestamp":1789069400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44161-026-00843-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["843"],"URL":"https:\/\/doi.org\/10.1038\/s44161-026-00843-1","relation":{},"ISSN":["2731-0590"],"issn-type":[{"value":"2731-0590","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.G., R.J.M., J.E.H., D.M.T. and E.R.P. are cofounders and scientific advisors of and hold equity in Dynomics, a biotechnology company focused on the development of heart failure therapeutics. J.W.M., D.A.E. and E.R.P. are named inventors on a provisional patent, owned by the Murdoch Children\u2019s Research Institute, for a gene therapy targeting\n                      ALPK3\n                      (PCT\/AU2025\/050228 \u2018Treatment methods for muscle-associated diseases\u2019). The other authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}